Analytical Data
-
Gene name
HLA-A*24:02&B2M&GP100 Intron 4(VYFFLPDHL) Monomer
- Application
-
Alternative Names
HLA-A*24:02; HLA-A2402; MHC I; gp100; Glycoprotein 100; ME20-M; P100; GP100 Intron 4; Intron 4
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59600.1 (G25-T305)&P61769
-
Expression Region
AAA59600.1 (G25-T305)&P61769 (I21-M119)&VYFFLPDHL
-
Molecular Weight
55-63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*24:02/B2M/GP100 Intron 4 (VYFFLPDHL) monomer recombinant protein is rooted in its significance in understanding immune responses against melanoma and other cancers. HLA-A*24:02 is a prevalent human leukocyte antigen (HLA) allele, particularly in Asian populations, and plays a critical role in the presentation of tumor-associated peptides to T cells. GP100, a melanoma antigen, is recognized by cytotoxic T lymphocytes (CTLs), and the peptide VYFFLPDHL derived from it is known to elicit strong immune responses. The inclusion of beta-2-microglobulin (B2M) is essential for the stability and proper folding of the HLA-A*24:02 molecule. By creating a monomeric form of this complex, researchers aim to investigate the structural and functional properties that influence T cell recognition and activation. This research is crucial for the development of peptide-based cancer vaccines and immunotherapies, as it helps delineate the mechanisms by which T cells can be effectively directed against specific tumor cells. Enhanced understanding of the HLA-peptide interactions may lead to improved strategies for personalized cancer treatments, ultimately contributing to better clinical outcomes for patients with melanoma and other malignancies.
